Third-generation Drugs and Antimicrobial Therapy to Combat Septic Infections

The severity of the septic process and the extent of organ dysfunction in patients require immediate admission to an ICU in hospital. To avoid extreme fatalities and admission to ICUs, healthcare companies in the sepsis therapeutics market are developing efficacious fourth- and fifth-generation drugs.

Revenue of cephalosporin drugs is projected to be the highest in 2027, in the sepsis therapeutics market, with an estimated value of ~US$ 2.2 billion. Thus, to gain positive outcome via clinical trials, manufacturers are collaborating with researchers & scientists to develop effective cephalosporin drugs. As such, healthcare institutions are approaching the combination therapy with third-generation cephalosporin and a tetracycline analogue to treat vibrio vulnificus infection in patients. This therapy has been gaining prominence in the sepsis therapeutics market, since the combination works as an 'in vitro' bactericidal activity against vibrio vulnificus.

Healthcare professionals are increasingly adopting antimicrobial therapy to minimize the damage caused by infections to the gut microbiome. As such, healthcare providers in the sepsis therapeutics market are delivering the right balance between the utilization of antimicrobials and the clinical need for treating specific signs and symptoms in patients.

sepsis therapeutics market

Request a sample to get extensive insights into the Sepsis Therapeutics Market?

Immunometabolism Delivers Insights on New Therapeutic Targets

Healthcare companies in the sepsis therapeutics market are increasing research on immunometabolism, as insights on immune regulation are helping manufacturers develop efficacious drugs. Since the early detection and treatment of sepsis is critical, researchers are studying the body’s natural and innate response to various classes of drugs by studying immunometabolism. To gain further insights, healthcare companies are running clinical trials involving antibiotics, fluids, and dialysis, to ensure blood flow to the affected organs. They are also devising methods of surgical therapies to remove damaged tissues.

As such, healthcare companies in the sepsis therapeutics market are trying to identify new therapeutic targets that could potentially reduce inflammatory response in patients. They are increasing research via animal testing by introducing lipopolysaccharide (LPS) in mice to see if the molecule can suppress the severity of inflammatory response.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Judicious Prescriptions and New Antimicrobial Agents Reduce Drug Resistance

Antimicrobials have a rapid and long-lasting effect on septic infections. However, antimicrobial resistance to gram-positive infections (GPIs) is emerging as a major public health threat to patients, worldwide. The growing prevalence of multidrug-resistant bacteria in patients has led to increased morbidity and mortality rates. This has created the issue of escalated treatment costs and prolonged hospitalization stay for patients. This is why, healthcare companies in the sepsis therapeutics market are developing new antimicrobial agents to reduce the resistance of drugs against gram-positive infections.

Healthcare companies are expected to develop a robust healthcare value and supply chain in the Asia Pacific region, as it is predicted for fast growth in the sepsis therapeutics market. For instance, stakeholders in the sepsis therapeutics market have observed the growing prevalence of methicillin resistant staphylococcus aureus bacteria in Indian patients that has led to the heavy consumption of antibiotics. Thus, stakeholders in the sepsis therapeutics market are recommending judicious prescription of antimicrobial agents, implementation of antibiotic stewardship programs, and conformation to suitable antibiotic policies developed by health commissions to reduce the problem of drug resistance in patients.

sepsis therapeutics market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Sepsis Therapeutics Market”?

Analysts’ View of Sepsis Therapeutics Market

The sepsis therapeutics market is predicted to exponentially grow from a value of ~US$ 3.2 billion that was accounted in 2018, to a value of ~US$ 6 billion by 2027. Healthcare providers are practicing early therapeutic plasma exchange in cases of septic shock in patients. This method is considered medically safe, and effective for septic shock patients. They are also introducing high doses of vasopressors for rapid hemodynamic improvement and favorable changes in the cytokine profile for patients observed with septic shock. However, in the case of GPIs, adverse effects related to safety and tolerability towards drugs is an ongoing challenge for healthcare companies. To overcome this challenge, manufacturers should introduce new antimicrobial agents in efficacious fourth- and fifth-generation drugs.

Sepsis Therapeutics Market: Overview

  • According to the latest report published by Transparency Market Research on the global sepsis therapeutics market for the historical year of 2017 and forecast period of 2019 to 2027, rise in investments in research & development and novel pipeline drugs are projected to boost the growth of the global sepsis therapeutics market during the forecast period.
  • The global sepsis therapeutics market generated ~US$ 3.2 Bn revenue in 2018, and is expected to expand at a CAGR of 7.5% from 2019 to 2027.

Novel Pipeline Drugs and Rise in Incidence Rate of Sepsis: A Key Driver

  • The geriatric population is prone to developing sepsis, and is expected to increase the patient pool across the world, which, in turn, is projected to drive the sepsis therapeutics market during the forecast period.
  • According to the United Nations University (UNU), the percentage of the world population above 65 years of age is anticipated to increase from 9% in 2010 to 16% by 2050.
  • Rise in the epidemiological burden of sepsis increases the demand for the development of drugs for the treatment of sepsis. This is likely to boost the growth of the sepsis therapeutics market.
  • Leading pharmaceutical companies are striving to address these unmet medical needs through new product development.
  • Asahi Kasei Corporation is planning to launch ART-123 by 2021 for the treatment of sepsis. The drug has shown positive results for phase III clinical trial for sepsis, which would support the advancement of drugs for phase IV studies.
  • New approval and commercialization of novel therapeutic drugs under clinical trial studies are projected to be a major driver of the global sepsis therapeutics market from 2019 to 2027.

Cephalosporin Drug Class Prominent

  • The cephalosporin segment dominated the global sepsis therapeutics market in 2018, and is expected to account for a major market share during the forecast period, as third-generation cephalosporins are commonly used to treat neonatal and infant sepsis. Cephalosporins also have the broadest gram-negative bacterial coverage. This is likely to drive the cephalosporin segment during the forecast period.
  • The others segment is projected to grow at significant CAGR during the forecast period. The use of combination therapy for the treatment of sepsis, such as cephalosporin plus an aminoglycoside, is a driving factor that is expected to propel the segment from 2019 to 2027.

Intravenous Administration Popular

  • The most common way to administer antibiotics is intravenously, as intravenous antibiotics reach tissues faster and at higher concentrations than oral antibiotics. The preference of the intravenous route for administration of drugs is expected to propel the segment during the forecast period.

North America to Dominate Global Sepsis Therapeutics Market

  • North America accounted for a major share of the global market in 2018, followed by Europe. The high prevalence and rise in incidence of sepsis in the U.S. and Canada, wide base of pharmaceutical companies in the U.S., and easy availability of drugs in the region were key factors responsible for the prominent share held by North America in the global sepsis therapeutics market in 2018.
  • According to a study published in the National Center for Biotechnology Information (NCBI), around 300 people per 100,000 individuals in the U.S. are affected by severe sepsis and septic shock
  • Europe was also an attractive market for sepsis therapeutics in 2018. High budget for research & development in the field of sepsis treatment and various initiatives taken by private and government institutions to promote awareness about sepsis are estimated to propel the market in Europe during the forecast period. Furthermore, well-established healthcare facilities, new product approvals, and commercialization and favorable medical reimbursement policies are anticipated to drive the market in the region.
  • The market in Asia Pacific is estimated to grow at a faster pace than other regions during the forecast period, due to increase in the focus on the development of healthcare infrastructure by public as well as private hospitals, along with a rise in the demand for novel therapeutics among a significant patient population. The sepsis therapeutics market in Asia Pacific is driven by a large pool of patients with sepsis in China and Japan, and rise in investments by leading players in the region for the establishment of distribution channels.

Global Sepsis Therapeutics Market: Competitive Landscape

  • Detailed profiles of the manufacturers of sepsis therapeutics have been provided in the report to evaluate their key product offerings, financials, business strategies, and recent developments.
  • Key players operating in the global sepsis therapeutics market include -
    • INOTREM S.A.
    • Mylan N.V.
    • Asahi Kasei Corporation
    • Pfizer, Inc.
    • GlaxoSmithKline plc
    • RegeneRx
    • Adrenomed AG
    • AtoxBio
    • Endacea, Inc.

Global Sepsis Therapeutics Market: Key Developments

Major manufacturers in the global sepsis therapeutics market are adopting research collaboration, purchase and distribution agreement, and new product development strategies to strengthen their product portfolios and geographic presence in the international market. Key developments in the global sepsis therapeutics market are:

  • In August 2019, Pfizer, Inc. partnered with GlaxoSmithKline plc to form a joint venture to create the world’s largest over-the-counter (OTC) business.
  • In November 2018, Adrenomed AG received US$ 27 Mn funding from Wellington Partners and HBM Healthcare Investments to be utilized toward the clinical development of Adrecizumab.

In the global sepsis therapeutics market report, we have discussed individual strategies, followed by company profiles of the manufacturers of sepsis drugs. The ‘competitive landscape’ section is included in the global sepsis therapeutics market report to provide readers with a dashboard view of the key players operating in the global sepsis therapeutics market.

Sepsis Therapeutics Market: Scope of the Report

A new study conducted on the global sepsis therapeutics market was published by Transparency Market Research (TMR). It presents a whole wealth of information on the key market dynamics, including the drivers, market trends, and challenges, as well as the structure of the sepsis therapeutics market. TMR’s study offers valuable information about the sepsis therapeutics market, to illustrate how growth will discern during the forecast period of 2019 - 2027.

Key indicators of market growth, which include pipeline analysis and Compound Annual Growth Rate (CAGR), have been elucidated in TMR’s study in a comprehensive manner. This data can help readers interpret the quantitative growth aspects of the sepsis therapeutics market for the duration of the forecast period.

An extensive analysis on leading market players’ business strategies is also featured in TMR’s study on the sepsis therapeutics market. This can help readers understand principal factors to foresee growth in the sepsis therapeutics market. In this study, readers can also find specific data on the qualitative and quantitative growth avenues of the sepsis therapeutics market, which will guide market players in making apt business decisions in the future.

Key Questions Answered in TMR’s Sepsis Therapeutics Market Study

  • What is the scope of growth of sepsis therapeutic companies in the pharmaceutical drugs sector?
  • What will be the Y-o-Y growth of the sepsis therapeutics market between the years 2019 and 2027?
  • What is the influence of the changing trends in the sepsis therapeutics market?
  • Will North America continue to remain the most profitable regional market for sepsis therapeutic providers?
  • Which factors will hamper the growth of the sepsis therapeutics market during the forecast period of 2019 to 2027?
  • Which are the leading companies in the global sepsis therapeutics market?

Sepsis Therapeutics Market: Research Methodology

A unique research methodology is utilized by TMR to conduct comprehensive research on the sepsis therapeutics market, and arrive at conclusions on the future growth prospects of the said market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary resources referred to by analysts during the production of the sepsis therapeutics market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, all of whom contributed to the production of TMR’s study on the sepsis therapeutics market, as a primary resource.

These primary and secondary resources provided exclusive information during the interviews, which serves as a validation from sepsis therapeutics market industry leaders. Access to an extensive internal repository and external proprietary databases allows for this report to address specific details and questions about the sepsis therapeutics market with high accuracy. The study also uses a top-down approach to assess the numbers for each segment, and a bottom-up approach to counter-validate them. This has helped in making TMR’s estimates on the future prospects of the sepsis therapeutics market much more reliable and accurate.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Segmentation of the Sepsis Therapeutics Market

TMR’s study on the sepsis therapeutics market includes information categorized into four sections - by drug class, by route of administration, by distribution channel, and by region. Changing industry trends and other crucial market dynamics that are associated with these four sections of the sepsis therapeutics market are discussed in detail.

Drug Class

Aminoglycosides

Cephalosporin

Glycopeptide Antibiotics

Others

Route of Administration

Intravenous

Oral

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Sepsis Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Sepsis Therapeutics Market Analysis and Forecasts, 2017–2027

5. Market Outlook

    5.1. Regulatory Scenario 

    5.2. Pipeline Analysis

6. Global Sepsis Therapeutics Market Analysis and Forecasts, by Drug Class 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2027

        6.3.1. Aminoglycosides

        6.3.2. Cephalosporin 

        6.3.3. Glycopeptide Antibiotics 

        6.3.4. Others 

    6.4. Market Attractiveness, by Drug Class 

7. Global Sepsis Therapeutics Market Analysis and Forecasts, by Route of Administration 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2027

        7.3.1. Intravenous 

        7.3.2. Oral

    7.4. Market Attractiveness, by Route of Administration 

8. Global Sepsis Therapeutics Market Analysis and Forecasts, by Distribution Channel 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2027

        8.3.1. Hospital Pharmacies 

        8.3.2. Retail Pharmacies 

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness, by Distribution Channel 

9. Global Sepsis Therapeutics Market Analysis and Forecasts, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness, by Region

10. North America Sepsis Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value  Forecast, by Drug Class, 2017–2027

        10.2.1. Aminoglycosides

        10.2.2. Cephalosporin 

        10.2.3. Glycopeptide Antibiotics 

        10.2.4. Others 

    10.3. Market Value Forecast, by Route of Administration, 2017–2027

        10.3.1. Intravenous 

        10.3.2. Oral

    10.4. Market Value  Forecast, by Distribution Channel, 2017–2027

        10.4.1. Hospital Pharmacies 

        10.4.2. Retail Pharmacies 

        10.4.3. Online Pharmacies

    10.5. Market Value  Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Drug Class 

        10.6.2. By Route of Administration 

        10.6.3. By Distribution Channel 

        10.6.4. By Country

11. Europe Sepsis Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2027

        11.2.1. Aminoglycosides

        11.2.2. Cephalosporin 

        11.2.3. Glycopeptide Antibiotics 

        11.2.4. Others 

    11.3. Market Value Forecast, by Route of Administration, 2017–2027

        11.3.1. Intravenous 

        11.3.2. Oral

    11.4. Market Value  Forecast, by Distribution Channel, 2017–2027

        11.4.1. Hospital Pharmacies 

        11.4.2. Retail Pharmacies 

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis 

        11.6.1. By Drug Class 

        11.6.2. By Route of Administration 

        11.6.3. By Distribution Channel 

        11.6.4. By Country/Sub-region

12. Asia Pacific Sepsis Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2027

        12.2.1. Aminoglycosides

        12.2.2. Cephalosporin 

        12.2.3. Glycopeptide Antibiotics 

        12.2.4. Others 

    12.3. Market Value Forecast, by Route of Administration, 2017–2027

        12.3.1. Intravenous 

        12.3.2. Oral

    12.4. Market Value Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies 

        12.4.2. Retail Pharmacies 

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis 

        12.6.1. By Drug Class 

        12.6.2. By Route of Administration 

        12.6.3. By Distribution Channel 

        12.6.4. By Country/Sub-region

13. Latin America Sepsis Therapeutics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2027

        13.2.1. Aminoglycosides

        13.2.2. Cephalosporin 

        13.2.3. Glycopeptide Antibiotics 

        13.2.4. Others 

    13.3. Market Value Forecast, by Route of Administration, 2017–2027

        13.3.1. Intravenous 

        13.3.2. Oral

    13.4. Market Value Forecast, by Distribution Channel, 2017–2027

        13.4.1. Hospital Pharmacies 

        13.4.2. Retail Pharmacies 

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis 

        13.6.1. By Drug Class 

        13.6.2. By Route of Administration 

        13.6.3. By Distribution Channel 

        13.6.4. By Country/Sub-region

14. Middle East & Africa Sepsis Therapeutics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value  Forecast, by Drug Class, 2017–2027

        14.2.1. Aminoglycosides

        14.2.2. Cephalosporin 

        14.2.3. Glycopeptide Antibiotics 

        14.2.4. Others 

    14.3. Market Value Forecast, by Route of Administration, 2017–2027

        14.3.1. Intravenous 

        14.3.2. Oral

    14.4. Market Value  Forecast, by Distribution Channel, 2017–2027

        14.4.1. Hospital Pharmacies 

        14.4.2. Retail Pharmacies 

        14.4.3. Online Pharmacies

    14.5. Market Value  Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis 

        14.6.1. By Drug Class 

        14.6.2. By Route of Administration 

        14.6.3. By Distribution Channel 

        14.6.4. By Country/Sub-region

15. Competitive Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Company Profiles

        15.2.1. Mylan N.V. 

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Product Portfolio

            15.2.1.3. SWOT Analysis

            15.2.1.4. Strategic Overview

            15.2.1.5. Financial Overview

        15.2.2. Asahi Kasei Corporation 

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Product Portfolio

            15.2.2.3. SWOT Analysis

            15.2.2.4. Strategic Overview

            15.2.2.5. Financial Overview

        15.2.3. Pfizer, Inc. 

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Product Portfolio

            15.2.3.3. SWOT Analysis

            15.2.3.4. Strategic Overview

            15.2.3.5. Financial Overview

        15.2.4. GlaxoSmithKline plc 

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Product Portfolio

            15.2.4.3. SWOT Analysis

            15.2.4.4. Strategic Overview

            15.2.4.5. Financial Overview

        15.2.5. RegeneRx

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Product Portfolio

            15.2.5.3. SWOT Analysis

            15.2.5.4. Strategic Overview

            15.2.5.5. Financial Overview

        15.2.6. Adrenomed AG 

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Product Portfolio

            15.2.6.3. Strategic Overview

        15.2.7. AtoxBio

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

        15.2.8. ENDACEA, INC. 

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Product Portfolio

            15.2.8.3. Strategic Overview

        15.2.9. INOTREM S.A 

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Product Portfolio

            15.2.9.3. Strategic Overview

List of Tables

Table 01: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 02: Global Sepsis Therapeutics Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 03: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 04: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 05: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 06: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 07: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 08: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 09: Europe Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 10: Europe Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 11: Europe Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 12: Europe Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 13: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 14: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 15: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 16: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 17: Latin America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 18: Latin America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 19: Latin America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 20: Latin America Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 21: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 22: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027

Table 24: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

List of Figures

Figure 01: Global Sepsis Therapeutics Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Sepsis Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2018 

Figure 04: Global Sepsis Therapeutics Market Revenue, by Drug Class (US$ Mn), 2018

Figure 03: Global Sepsis Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2018 

Figure 05: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast, 2017–2027

Figure 07: Global Sepsis Therapeutics Market Value Share, by Route of Administration, 2018

Figure 09: Global Sepsis Therapeutics Market Value Share, by Region, 2018

Figure 06: Global Sepsis Therapeutics Market Value Share, by Drug Class, 2018

Figure 08: Global Sepsis Therapeutics Market Value Share, by Distribution Channel, 2018

Figure 10: Regulatory Approval Process - U.S.  

Figure 11: Regulatory Approval Process - Canada

Figure 12: Regulatory Approval Process - Europe 

Figure 13: Regulatory Approval Process - Japan

Figure 14: Regulatory Approval Process - India

Figure 15: Global Sepsis Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 16: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Aminoglycosides, 2017–2027

Figure 17: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Cephalosporin, 2017–2027

Figure 18: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Glycopeptide Antibiotics, 2017–2027

Figure 19: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017–2027

Figure 20: Global Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 21: Global Sepsis Therapeutics Market Value Share (%), by Route of Administration, 2018 and 2027

Figure 22: Global Sepsis Therapeutics Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Intravenous, 2017–2027

Figure 23: Global Sepsis Therapeutics Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Oral, 2017–2027

Figure 24: Global Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 25: Global Sepsis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2027

Figure 26: Global Sepsis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

Figure 27: Global Sepsis Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

Figure 28: Global Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

Figure 29: Global Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 30: Global Sepsis Therapeutics Market Value Share Analysis, by Region 2018 and 2027

Figure 31: Global Sepsis Therapeutics Market Attractiveness, by Region, 2019–2027

Figure 32: North America Sepsis Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 33: North America Sepsis Therapeutics Market Value Share (%) Analysis, by Country, 2018 and 2027

Figure 34: North America Sepsis Therapeutics Market Attractiveness Analysis, by Country, 2019?2027

Figure 35: North America Sepsis Therapeutics Market Value Share (%) Analysis, by Drug Class, 2018 and 2027

Figure 36: North America Sepsis Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027

Figure 37: North America Sepsis Therapeutics Market Value Share (%) Analysis, by Route of Administration, 2018 and 2027

Figure 38: North America Sepsis Therapeutics Market Attractiveness Analysis, by Route of Administration, 2019–2027

Figure 39: North America Sepsis Therapeutics Market Value Share (%) Analysis, by Distribution Channel, 2018 and 2027

Figure 40: North America Sepsis Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 41: Europe Sepsis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 42: Europe Sepsis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 43: Europe Sepsis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019?2027

Figure 44: Europe Sepsis Therapeutics Market Value Share Analysis (%), by Drug Class, 2018 and 2027

Figure 45: Europe Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 46: Europe Sepsis Therapeutics Market Value Share Analysis (%), by Route of Administration, 2018 and 2027

Figure 47: Europe Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 48: Europe Sepsis Therapeutics Market Value Share Analysis (%), by Distribution Channel, 2018 and 2027

Figure 49: Europe Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 50: Asia Pacific Sepsis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 51: Asia Pacific Sepsis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 52: Asia Pacific Sepsis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 53: Asia Pacific Sepsis Therapeutics Market Value Share Analysis (%), by Drug Class, 2018 and 2027

Figure 54: Asia Pacific Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 55: Asia Pacific Sepsis Therapeutics Market Value Share Analysis (%), by Route of Administration, 2018 and 2027

Figure 56: Asia Pacific Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 57: Asia Pacific Sepsis Therapeutics Market Value Share Analysis (%), by Distribution Channel, 2018 and 2027

Figure 58: Asia Pacific Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 59: Latin America Sepsis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 60: Latin America Sepsis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 61: Latin America Sepsis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 62: Latin America Sepsis Therapeutics Market Value Share Analysis (%), by Drug Class, 2018 and 2027

Figure 63: Latin America Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 64: Latin America Sepsis Therapeutics Market Value Share Analysis (%), by Route of Administration, 2018 and 2027

Figure 65: Latin America Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 66: Latin America Sepsis Therapeutics Market Value Share Analysis (%), by Distribution Channel, 2018 and 2027

Figure 67: Latin America Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Figure 68: Middle East & Africa Sepsis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

Figure 69: Middle East & Africa Sepsis Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 70: Middle East & Africa Sepsis Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019-2027

Figure 71: Middle East & Africa Sepsis Therapeutics Market Value Share Analysis (%), by Drug Class, 2018 and 2027

Figure 72: Middle East & Africa Sepsis Therapeutics Market Attractiveness, by Drug Class, 2019–2027

Figure 73: Middle East & Africa Sepsis Therapeutics Market Value Share Analysis (%), by Route of Administration, 2018 and 2027

Figure 74: Middle East & Africa Sepsis Therapeutics Market Attractiveness, by Route of Administration, 2019–2027

Figure 75: Middle East & Africa Sepsis Therapeutics Market Value Share Analysis (%), by Distribution Channel, 2018 and 2027

Figure 76: Middle East & Africa Sepsis Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Sepsis Therapeutics Market